Cargando…

Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study

The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD). Either 0.6 mg or 0.9 mg liraglutide was subcutaneously administered daily to 10 Japanese type 2 diabetic patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osonoi, Takeshi, Saito, Miyoko, Tamasawa, Atsuko, Ishida, Hidenori, Tsujino, Daisuke, Nishimura, Rimei, Utsunomiya, Kazunori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272272/ https://www.ncbi.nlm.nih.gov/pubmed/25526642 http://dx.doi.org/10.1371/journal.pone.0113468

Ejemplares similares

Efficacy of ipragliflozin as monotherapy or as add‐on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics
por: Osonoi, Takeshi, et al.
Publicado: (2017)

Relationships between lifestyle patterns and cardio-renal-metabolic parameters in patients with type 2 diabetes mellitus: A cross-sectional study
por: Ogihara, Takeshi, et al.
Publicado: (2017)

Poor sleep quality is associated with increased arterial stiffness in Japanese patients with type 2 diabetes mellitus
por: Osonoi, Yusuke, et al.
Publicado: (2015)

Relationship between dietary patterns and risk factors for cardiovascular disease in patients with type 2 diabetes mellitus: a cross-sectional study
por: Osonoi, Yusuke, et al.
Publicado: (2016)

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
por: Osonoi, Takeshi, et al.
Publicado: (2019)

Relationships Among Conventional Cardiovascular Risk Factors and Lifestyle Habits With Arterial Stiffness in Type 2 Diabetic Patients
por: Hamamura, Misako, et al.
Publicado: (2017)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
por: Takahashi, Hiroshi, et al.
Publicado: (2018)

Can Fasting Glucose Levels or Post-Breakfast Glucose Fluctuations Predict the Occurrence of Nocturnal Asymptomatic Hypoglycemia in Type 1 Diabetic Patients Receiving Basal-Bolus Insulin Therapy with Long-Acting Insulin?
por: Mitsuishi, Sumie, et al.
Publicado: (2015)

24-Hour Glycemic Variations in Drug-Naïve Patients with Type 2 Diabetes: A Continuous Glucose Monitoring (CGM)-Based Study
por: Ando, Kiyotaka, et al.
Publicado: (2013)

Prediction of nocturnal hypoglycemia unawareness by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes receiving insulin degludec: A pilot study
por: Takahashi, Hiroshi, et al.
Publicado: (2017)

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
por: Sakamoto, Masaya, et al.
Publicado: (2012)

Biphasic insulin aspart‐30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once‐daily insulin regimens using continuous glucose monitoring
por: Tsujino, Daisuke, et al.
Publicado: (2017)

The relationship between HbA1c values and the occurrence of hypoglycemia as assessed by continuous glucose monitoring in patients with type 1 diabetes
por: Tsujino, Daisuke, et al.
Publicado: (2016)

Effect of the FreeStyle Libre™ flash glucose monitoring system on glycemic control in individuals with type 2 diabetes treated with basal–bolus insulin therapy: An open label, prospective, multicenter trial in Japan
por: Ogawa, Wataru, et al.
Publicado: (2020)

Non-Alcoholic Fatty Liver Disease Markers Associated with Fasting Serum Insulin and Urinary Albumin Excretion Independent of Fasting Plasma Glucose
por: Katoh, Shuichi, et al.
Publicado: (2020)

Breakfast skipping is associated with persistently increased arterial stiffness in patients with type 2 diabetes
por: Mita, Tomoya, et al.
Publicado: (2020)

Lower intake of saturated fatty acids is associated with persistently higher arterial stiffness in patients with type 2 diabetes
por: Mita, Tomoya, et al.
Publicado: (2020)

Four‐year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes
por: Kobori, Mariko, et al.
Publicado: (2016)

S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy
por: Kondo, Shinnosuke, et al.
Publicado: (2021)

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes
por: Nishimura, Rimei, et al.
Publicado: (2019)

Population‐based cross‐sectional study on insulin resistance and insulin‐secretory capacity in Japanese school children
por: Nishimura, Rimei, et al.
Publicado: (2017)

Continuous glucose monitoring with Humalog Mix 25 versus Humalog Mix 50, twice daily: A comparative pilot study -Results from the Jikei-EValuation of insulin Lispro mixture on pharmacodynamics and glycemic VariancE (J-EVOLVE) study
por: Nishimura, Rimei, et al.
Publicado: (2010)

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes: The Japan Diabetes Complication and its Prevention prospective study 5
por: Shikata, Kenichi, et al.
Publicado: (2019)

Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients
por: Hariya, Natsuyo, et al.
Publicado: (2014)

Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis
por: Luketin, Mirko, et al.
Publicado: (2021)

Age at Transition from Pediatric to Adult Care Has No Relationship with Mortality for Childhood-Onset Type 1 Diabetes in Japan: Diabetes Epidemiology Research International (DERI) Mortality Study
por: Onda, Yoshiko, et al.
Publicado: (2016)

Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2019)

Targeting Redox Imbalance as an Approach for Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2020)

Successful control of a case of severe insulin allergy with liraglutide
por: Kawanami, Daiji, et al.
Publicado: (2013)

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes
por: Denimal, Damien, et al.
Publicado: (2023)

The Physiology, Pathology, and Therapeutic Interventions for ROCK Isoforms in Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2020)

Endothelial Dysfunction in Diabetes
por: Takeda, Yusuke, et al.
Publicado: (2020)

Effects of hemodialysis on plasma oxylipins
por: Gollasch, Benjamin, et al.
Publicado: (2020)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi, Takeshi, et al.
Publicado: (2020)

Plasma Endocan as a Predictor of Cardiovascular Event in Patients with End-Stage Renal Disease on Hemodialysis
por: Kim, Jin Sug, et al.
Publicado: (2020)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis
por: Plum, Anne, et al.
Publicado: (2013)

ROCK Inhibition May Stop Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q5ldpp3sgdi3fqn9026n76t97a